- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Flecainide Achieves Faster Cardioversion Than Amiodarone in Selected CAD Patients, Study Finds

Atrial fibrillation (AF) is among the most common cardiac arrhythmias encountered in emergency departments, frequently requiring pharmacological or electrical cardioversion. Flecainide, a class Ic antiarrhythmic drug, is highly effective in restoring sinus rhythm but has traditionally been avoided in patients with coronary artery disease (CAD) because of concerns about ventricular proarrhythmia and mortality following the Cardiac Arrhythmia Suppression Trial (CAST). However, whether these restrictions should apply equally to patients with stable CAD without active or residual myocardial ischaemia remains an important clinical question.
A new randomised clinical trial published in Heart Rhythm suggests that intravenous flecainide may achieve faster and more effective cardioversion than amiodarone in carefully selected patients with CAD and recent-onset paroxysmal AF.
The study, titled “Efficacy and Safety of Flecainide Versus Amiodarone for the Cardioversion of Paroxysmal Atrial Fibrillation in Patients With Coronary Artery Disease Without Evidence of Residual Ischemia: The FLECA-ED Randomized Clinical Trial,” was conducted by Panagiotis-Anastasios Tsioufis and colleagues in Greece.
This investigator-initiated, multicentre, open-label randomised trial enrolled 87 patients presenting to emergency departments with paroxysmal AF and documented CAD without evidence of active or residual ischaemia.
Patients were randomly assigned to intravenous flecainide (42 patients) or intravenous amiodarone (45 patients). All underwent 24-hour ambulatory electrocardiographic monitoring.
The primary efficacy endpoint was conversion to sinus rhythm within six hours. The primary safety endpoint included ventricular arrhythmias, premature ventricular complexes, significant hypotension and bradycardia.
The investigators reported several important findings:
• Sinus rhythm was restored within six hours in 85.7% of patients receiving flecainide compared with 40.0% receiving amiodarone (P<0.001).
• The median time to cardioversion was 20 minutes with flecainide versus 244 minutes with amiodarone (P<0.001).
• Hospital admission was required in 14.3% of the flecainide group compared with 60.0% of the amiodarone group (P<0.001).
• No ventricular proarrhythmic events were observed within 24 hours in either treatment group.
• No deaths were recorded during 30-day follow-up.
These findings suggest that intravenous flecainide can restore sinus rhythm more rapidly than amiodarone in selected patients with CAD, potentially reducing emergency department observation time and hospital admissions.
The results are particularly interesting because conventional restrictions on flecainide originated largely from CAST, which demonstrated increased mortality with class Ic antiarrhythmic agents in patients following myocardial infarction with ventricular ectopy.
However, the population studied in FLECA-ED differed from that historical high-risk population. Patients were selected specifically for the absence of active or residual myocardial ischaemia.
The findings therefore raise an important question: should all patients with CAD be considered equally unsuitable for flecainide therapy?
Nevertheless, the trial has important limitations. Only 87 patients were enrolled, the study was open-label, and safety monitoring was relatively short. The absence of ventricular proarrhythmia in this small population cannot establish long-term safety or exclude uncommon but potentially fatal arrhythmias.
Furthermore, the results concern acute intravenous cardioversion and should not be extrapolated to chronic oral flecainide therapy or patients with significant ventricular dysfunction, myocardial scar or ongoing ischaemia.
For practising cardiologists, the study provides preliminary evidence supporting a more individualised assessment of antiarrhythmic treatment in stable CAD. However, existing contraindications and guideline precautions should remain in place pending larger confirmatory studies.
Clinical Message: Intravenous flecainide achieved substantially faster and more frequent cardioversion than amiodarone in selected patients with coronary artery disease without active or residual ischaemia. Although no serious ventricular proarrhythmias were observed, the small trial cannot establish safety. The findings are hypothesis-generating and should not prompt routine flecainide use in patients with CAD outside established prescribing recommendations.
Reference:
Tsioufis PA, Tsiachris D, Argyriou N, et al. Efficacy and safety of flecainide vs amiodarone for the cardioversion of paroxysmal atrial fibrillation in patients with coronary artery disease without evidence of residual ischemia: The FLECA-ED randomized clinical trial. Heart Rhythm. Published online October 6, 2026.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

